In addition to the agents listed below, colchicine, alendronate, and warfarin, amongst other therapies, have been shown to be potentially beneficial for the treatment of calcinosis. Prednisone is the first-line therapy for muscle involvement in dermatomyositis. Chloroquine colon cancer Retinal toxicity plaquenil reversible Hydroxychloroquine 200 mg price increase Chloroquine resistant falciparum malaria The study is based on mycophenolate mofetil and hydroxychloroquine sulfate the active ingredients of Cellcept and Plaquenil, respectively, and Cellcept and Plaquenil the brand names. Other drugs that have the same active ingredients e.g. generic drugs are not considered. In general, treatment for the muscle involvement associated with dermatomyositis requires the use of glucocorticoids. Treatment for the skin findings associated with dermatomyositis includes sun avoidance, sunscreens, topical glucocorticoids, anti-malarial agents, methotrexate, mycophenolate mofetil, and/or intravenous immunoglobulin IVIg. INTRODUCTION. Dermatomyositis DM and polymyositis PM are two classic forms of inflammatory myopathy. Most patients respond to initial therapy, and some achieve sustained disease control either off all therapy or with low-dose maintenance therapy. Antimalarials, particularly hydroxychloroquine, may be useful for cutaneous disease; however, the majority of patients with cutaneous involvement require additional immunomodulatory medications for adequate control. The dose is altered according to the response of the patient’s condition. Mycophenolate and plaquenil for dermatomyositis Polymyositis PM - Muscular Dystrophy Association, Dermatomyositis - NORD National Organization for Rare Disorders Hydroxychloroquine burning scalpSurfactant protein c deficiency hydroxychloroquine Mycophenolate Mofetil, a Possible Therapeutic Agent for Children with Juvenile Dermatomyositis Kelly A Rouster-Stevens, MD, PharmD, 1 Gabrielle A Morgan, MA, 2 Deli Wang, MD, PhD, 3 and Lauren M Pachman, MD 2, 4 Mycophenolate Mofetil, a Possible Therapeutic Agent for.. UpToDate. Juvenile Dermatomyositis. Skin Disease In Dermatomyositis --What Patients And Their Families Often Want To Know--Richard D. Sontheimer M. D. 1 Dermatology Online Journal 81 6 1. John S. Strauss Endowed Chair in Dermatology, Professor and Head, Department of Dermatology, University of Iowa College of Medicine/University of Iowa Hospitals & Clinics, University of Iowa Health Care Caregivers administering mycophenolate should wear gloves when handling it due to concern with pregnancy risks and effects on the immune system. In adults, mycophenolate is typically taken twice daily for a total dose of 2 - 3 grams 2000 - 3000mg per day, although this dosage may be reduced in people with underlying kidney problems. Amyopathic Dermatomyositis ADM and Hypomyopathic Dermatomyositis HDM, together referred to as Clinically Amyopathic Dermatomyositis CADM, are subsets of Dermatomyositis DM, one of the Idiopathic Inflammatory Myopathies. The cause is unclear and there is no cure.